Phase 3 Readout
AMRX: Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (
December 31, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Amneal Pharmaceuticals, Inc. (AMRX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (
- Indication
- Stage IV Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Advanced Lung Non-Squamous Non-Small Cell Carcinoma